Medication adherence has an impact on disease activity in rheumatoid arthritis: A systematic review and meta-analysis

Patient Preference and Adherence

Volumn 11, Issue , 2017, Pages 1343-1356

  Li, Lin ^a   Cui, Yafei ^a   Yin, Rulan ^b   Chen, Shengnan ^a   Zhao, Qian ^a   Chen, Haoyang ^a   Shen, Biyu ^a  

^a NANTONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Disease activity; Medication adherence; Meta analysis; Rheumatoid arthritis

Indexed keywords

EID: 85027888580     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S140457     Document Type: Review

References (34)

1. Wong PK. Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe. Rheumatol Int. 2016; 36(11):1535–1542.
2. Lupoli R, Pizzicato P, Scalera A, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther. 2016;18(1):297.
3. Richards JS, Cannon GW, Hayden CL, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(12):1864–1870.
4. Jorgensen TS, Kristensen LE, Christensen R, et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford). 2015;54(12):2156–2165.
5. Joplin S, van der Zwan R, Joshua F, Wong PK. Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int. 2015;2015:150658.
6. Pasma A, Schenk CV, Timman R, et al. Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther. 2015;17(1):281.
7. Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci. 2015;349(2):151–156.
8. Curtis JR, Bykerk VP, Aassi M, Schiff M. Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol. 2016;43(11):1997–2009.
9. Contreras-Yanez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther. 2015;17:177.
10. Pasma A, Schenk C, Timman R, et al. Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment? PLos One. 2017;12(2):e0171070.
11. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheumatic Dis Clin North Am. 2009;35(4):745–757.
12. Sode J, Vogel U, Bank S, et al. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. PLoS One. 2014;9(6):e100361.
13. Mjaavatten MD, Radner H, Yoshida K, et al. Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2015;44(4): 399–404.
14. Alemao E, Joo S, Kawabata H, et al. Effects of achieving target measures in rheumatoid arthritis on functional status, quality of life, and resource utilization: analysis of clinical practice data. Arthritis Care Res (Hoboken). 2016;68(3):308–317.
15. Arshad N, Ahmad NM, Saeed MA, Khan S, Batool S, Farman S. Adherence to methotrexate therapy in rheumatoid arthritis. Pak J Med Sci. 2016;32(2):413–417.
16. Contreras-Yanez I, Ponce DLS, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci. 2010; 340(4):282–290.
17. Cannon GW, Mikuls TR, Hayden CL, et al. Merging veterans affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res. 2011;63(12):1680–1690.
18. Salaffi F, Carotti M, Di Carlo M, Farah S, Gutierrez M. Adherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritis. J Clin Rheumatol. 2015;21(8):419–425.
19. Fransen J, Laan R, van der Laar M, Huizinga T, van Riel P. Influence of guideline adherence on outcome in a randomized controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis. Ann Rheum Dis. 2004;63(10):1222–1226.
20. Xia Y, Yin R, Fu T, et al. Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adherence. 2016;10:735–742.
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint–preferred reporting items for systematic reviews and meta-analyzes: the PRISMA statement. Phys Ther. 2009;89(9):873–880.
22. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
23. Mata DA, Ramos MA, Bansal N, et al. Prevalence of depression and depressive symptoms among resident physicians: a systematic review and meta-analysis. JAMA. 2015;314(22):2373–2383.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
25. Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005; 24(9):1291–1306.
26. Jeffrey C. Valentine TDPH. How many studies do you need a primer on statistical power for meta-analysis. J Edu Behav Stat. 2010; 35(2):215–247.
27. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Therapeutics. 2011;33(7):901–913.
28. DiMatteo MR GPLH. Patient adherence and medical treatment outcomes. Med Care. 2002;40:794–811.
29. Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M. Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatol Int. 2017;37(6):897–904.
30. Bluett J, Morgan C, Thurston L, et al. Impact of inadequate adherence on response to subcutaneously administered anti-tumor necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology. 2015; 54(3):494–499.
31. Markusse IM, Dirven L, Han KH, et al. Evaluating adherence to a treat-to-target protocol in recent-onset rheumatoid arthritis: reasons for compliance and hesitation. Arthritis Care Res. 2016;68(4):446–453.
32. Lee P, Tan LJ. Drug compliance in outpatients with rheumatoid arthritis. Aust N Z J Med. 1979;9(3):274–277.
33. Kumar K, Raza K, Gill P, Greenfield S. The impact of using musculoskeletal ultrasound imaging and other influencing factors on medication adherence in patients with rheumatoid arthritis: a qualitative study. Patient Prefer Adherence. 2016;10:1091–1100.
34. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155–159.